We are live on ! Find out more
ENTA icon

Enanta Pharmaceuticals
ENTA

111 hedge funds and large institutions have $408M invested in Enanta Pharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 48 increasing their positions, 28 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

118% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 11

71% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 28

13% more funds holding

Funds holding: 98 → 111 (+13)

3% less capital invested

Capital invested by funds: $419M → $408M (-$11.2M)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

61% less call options, than puts

Call options by funds: $638K | Put options by funds: $1.62M

Holders
111
Holders Change
+13
Holders Change %
+13.27%
% of All Funds
3.22%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.09%
New
24
Increased
48
Reduced
28
Closed
11
Calls
$638K
Puts
$1.62M
Net Calls
-$981K
Net Calls Change
-$1.16M

Top Buyers

1
Marshall Wace
Marshall Wace
United Kingdom
+$12.5M
2
SAM
Senzar Asset Management
New York
+$12.4M
3
GC
Guggenheim Capital
Illinois
+$7.68M
4
EAM
Eagle Asset Management
Florida
+$4.92M
5
NI
Numeric Investors
Massachusetts
+$4.43M

Top Sellers

1
RCM
RA Capital Management
Massachusetts
-$51.4M
2
WSA
Wall Street Associates
California
-$2.4M
3
AAM
Aureus Asset Management
Massachusetts
-$2.39M
4
CCM
Cadence Capital Management
Massachusetts
-$2.38M
5
Allianz Asset Management
Allianz Asset Management
Germany
-$1.62M
Name Holding Trade Value Shares
Change 		Change in
Stake
BBA
26
Baker Bros. Advisors
New York
$2.98M – – –
TI
27
Turner Investments
Pennsylvania
$2.97M -$1.2M -30,040 -29%
CCM
28
Cadence Capital Management
Massachusetts
$2.9M -$2.38M -59,620 -45%
BA
29
BlackRock Advisors
Delaware
$2.78M +$1.13M +28,226 +67%
Bank of New York Mellon
30
Bank of New York Mellon
New York
$2.66M +$420K +10,546 +19%
EI
31
EAM Investors
California
$2.48M -$71.2K -1,786 -3%
TCIM
32
TIAA CREF Investment Management
New York
$2.37M -$593K -14,877 -20%
AQR Capital Management
33
AQR Capital Management
Connecticut
$2.34M +$1.53M +38,300 +183%
Millennium Management
34
Millennium Management
New York
$2.25M +$2.05M +51,398 +949%
Geode Capital Management
35
Geode Capital Management
Massachusetts
$2.2M +$531K +13,320 +31%
Charles Schwab
36
Charles Schwab
California
$2.17M +$1.48M +37,180 +211%
CIP
37
Convergence Investment Partners
Florida
$2.1M +$2.12M +53,130 New
GAM
38
Gotham Asset Management
New York
$2.07M +$2.08M +52,230 New
ACM
39
Apex Capital Management
Ohio
$1.99M +$206K +5,157 +11%
Goldman Sachs
40
Goldman Sachs
New York
$1.88M +$1.69M +42,468 +850%
Citadel Advisors
41
Citadel Advisors
Florida
$1.84M +$1.57M +39,333 +545%
PPA
42
Parametric Portfolio Associates
Washington
$1.81M +$1.57M +39,351 +609%
RFC
43
Russell Frank Company
Washington
$1.8M -$63.6K -1,596 -3%
AI
44
Analytic Investors
California
$1.68M -$481K -12,055 -22%
New York State Common Retirement Fund
45
New York State Common Retirement Fund
New York
$1.63M -$635K -15,930 -28%
Barclays
46
Barclays
United Kingdom
$1.5M -$1.22M -30,540 -44%
PP
47
PDT Partners
New York
$1.43M +$1.44M +36,096 New
SIM
48
Spark Investment Management
New York
$1.42M +$909K +22,800 +175%
GTC
49
Ghost Tree Capital
New York
$1.39M -$598K -15,000 -30%
DILH
50
Dai-ichi Life Holdings
Japan
$1.33M -$25.4K -637 -2%
1
2
3 4 5

ENTA Hedge Fund Activity: Q3 2014 in Review

111 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q3 2014, worth a combined $408M — down 2.7% from $419M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new ENTA positions and 11 closed out — a net gain of 13 holders — while 48 added to existing stakes and 28 trimmed.

The largest buyer was Marshall Wace, adding an estimated $12.5M. The largest seller was RA Capital Management, cutting an estimated $51.4M.

  • 111 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q3 2014, up from 98 in Q2 2014.
  • Funds reported $408M of Enanta Pharmaceuticals stock for Q3 2014, down 2.7% quarter-over-quarter.
  • 24 funds opened new Enanta Pharmaceuticals positions in Q3 2014 and 11 closed out, a net change of +13 holders.
  • The largest Enanta Pharmaceuticals buyer in Q3 2014 was Marshall Wace, an estimated $12.5M added.
  • The largest Enanta Pharmaceuticals seller in Q3 2014 was RA Capital Management, an estimated $51.4M sold.

Based on aggregated 13F filings for Q3 2014.